Mylan launches Efavirenz in USA, first generic version of BMS’s HIV type 1 treatment Sustiva
Mylan is launching Efavirenz Tablets USP, 600 mg, in the USA, the first generic version of Bristol-Myers Squibb’s Sustiva, which…
Pharmaceuticals, Biotechnology and Life Sciences
Mylan is launching Efavirenz Tablets USP, 600 mg, in the USA, the first generic version of Bristol-Myers Squibb’s Sustiva, which…
Faron Pharmaceuticals has gotten a patent from European Patent office, for Clever-1 antibodies, the mechanism for the Clevegen, the treatment…
Novo Nordisk has published the results for semaglutide from a study aiming to test the treatment for type 2 diabetes.
Stada has announced the new name to succeed the current CEO Claudio Albrecht in September this year.
Vertex Pharmaceuticals will move its cystic fibrosis treatment VX-659 and VX-445 into Phase 3, the company said Wednesday, after the initial…
Nordic Nanovector ASA has appointed Malene Brondberg as Vice President, Investor Relations and Corporate Communications. Malene will lead the engagement and…
Alkermes will attempt to get new approval from the USFDA for its investigational drug for treating major depressive disorder (MDD).
Gemphire Therapeutics, a US based clinical-stage biopharmaceutical company focused on therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), has…
Filament BioSolutions, a New York-based clinical nutrition therapeutics specialist from announced a collaboration with the University of Ottawa and Children’s…
AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients…